top of page
![](https://static.wixstatic.com/media/11062b_6a134fc09ea34833a17d295e295ab517f000.jpg/v1/fill/w_288,h_162,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/11062b_6a134fc09ea34833a17d295e295ab517f000.jpg)
![Digital Autoradiography](https://static.wixstatic.com/media/f0f065_95d68271f45b46b7baedb7bf4e013fdf~mv2.png/v1/fill/w_252,h_78,al_c,q_85,enc_auto/f0f065_95d68271f45b46b7baedb7bf4e013fdf~mv2.png)
Real-Time Digital Autoradiography
![](https://static.wixstatic.com/media/f0f065_afae512ed6c64cb2a817db22a2c2fa97~mv2.png/v1/fill/w_170,h_170,al_c,q_85,usm_0.66_1.00_0.01/f0f065_afae512ed6c64cb2a817db22a2c2fa97~mv2.png)
Characterization of a double-sided silicon strip detector autoradiography system
Örbom et al. used the ability of the Biomolex 700 to distinguish different radioactive energy profiles in a prostate cancer study. Here the tumor distribution of 125I-labeled monoclonal antibody targeting Prostate Specific Antigen was compared to co-injected 18F-FDG or 18F-choline (Evans-Axelsson et al. "Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone." Cancer Biother Radiopharm. 2012 May;27(4):243-51, PMID 22489659)
Please reload
bottom of page